Kentaro Yoshioka

Dr. Kentaro Yoshioka


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2014 in Hepatology Research
Verified
Journal Article
Closed access
PDF file
KYKentaro Yoshioka
Kentaro Yoshioka
SHSenju Hashimoto
Senju Hashimoto
NKNaoto Kawabe
Naoto Kawabe

6 August 2011 in Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
KOKeisuke Osakabe
Keisuke Osakabe
NINaohiro Ichino
Naohiro Ichino
TNToru Nishikawa
Toru Nishikawa
HSHiroko Sugiyama
Hiroko Sugiyama
MKMiho Kato
Miho Kato
KYKentaro Yoshioka
Kentaro Yoshioka

20 February 2007 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
KHKazuhiko Hayashi
Kazuhiko Hayashi
YKYoshiaki Katano
Yoshiaki Katano
YTYasushi Takeda
Yasushi Takeda
THTakashi Honda
Takashi Honda
MIMasatoshi Ishigami
Masatoshi Ishigami
HTHidenori Toyoda
Hidenori Toyoda


13 February 2015 in SpringerPlus
Verified
Journal Article
Open access
PDF file
KNKazunori Nakaoka
Kazunori Nakaoka
SHSenju Hashimoto
Senju Hashimoto
NKNaoto Kawabe
Naoto Kawabe
YNYoshifumi Nitta
Yoshifumi Nitta
MMMichihito Murao
Michihito Murao
KYKentaro Yoshioka
Kentaro Yoshioka
To investigate associations between patatin-like phospholipase domain-containing 3 (PNPLA3) genotypes and fibrosis and hepatocarcinogenesis in Japanese chronic hepatitis C (CHC) patients. Two hundred and thirty-one patients with CHC were examined for PNPLA3 genotypes, liver stiffness measurements (LSM), and hepatocellular carcinoma (HCC) from May 2010 to October 2012 at Fujita Health University Hospital. The rs738409 single nucleotide polymorphism (SNP) encoding for a functional PNPLA3 I148M protein variant was genotyped using a TaqMan predesigned SNP genotyping assay. LSM was determined as the velocity of a shear wave (Vs) with an acoustic radiation force impulse. Vs cut-off values for cirrhosis were set at 1.55 m/s. We excluded CHC patients with a sustained virological response or relapse after interferon treatment. PNPLA3 genotypes were CC, CG, and GG for 118, 72, and 41 patients, respectively. Multivariable logistic regression analysis selected older age (OR = 1.06; 95% CI: 1.03–1.09; p < 0.0001), higher body mass index (BMI) (OR= 1.12; 95% CI: 1.03–1.22; p = 0.0082), and PNPLA3 genotype GG (OR = 2.07; 95% CI: 0.97–4.42; p = 0.0599) as the factors independently associated with cirrhosis. When 137 patients without past history of interferon treatment were separately assessed, multivariable logistic regression analysis selected older age (OR = 1.05; 95% CI: 1.02–1.09; p = 0.0034), and PNPLA3 genotype GG (OR = 3.35; 95% CI: 1.13–9.91; p = 0.0291) as the factors independently associated with cirrhosis. Multivariable logistic regression analysis selected older age (OR = 1.12; 95% CI: 1.07–1.17; p < 0.0001), PNPLA3 genotype GG (OR = 2.62; 95% CI: 1.15–5.96; p = 0.0218), and male gender (OR = 1.83; 95% CI: 0.90–3.71); p = 0.0936) as the factors independently associated with HCC. PNPLA3 genotype I148M is one of risk factors for developing HCC in Japanese CHC patients, and is one of risk factors for progress to cirrhosis in the patients without past history of interferon treatment.

1 January 2010 in World Journal of Gastroenterology
Verified
Journal Article
Open access
NINaohiro Ichino
Naohiro Ichino
KOKeisuke Osakabe
Keisuke Osakabe
TNToru Nishikawa
Toru Nishikawa
HSHiroko Sugiyama
Hiroko Sugiyama
MKMiho Kato
Miho Kato
KYKentaro Yoshioka
Kentaro Yoshioka
AIM: To construct and evaluate a new non-invasive fibrosis index for assessment of the stage of liver fibrosis. METHODS: A new fibrosis index (Fibro-Stiffness index) was developed in 165 of 285 patients with chronic hepatitis C, and was validated in the other 120 patients where liver biopsy was performed. Its usefulness was compared with liver stiffness (LS) measured by FibroScan, the aminotransferase-to-platelet ratio index, the Forns index and the FibroIndex. RESULTS: The Fibro-Stiffness index consists of LS, platelet count and prothrombin time. The values of the Fibro-Stiffness index differed significantly between neighboring fibrosis stages except F0-F1. The area under the receiver operating characteristics curves of the Fibro-Stiffness index for prediction of F ≥ 2 (0.90), F ≥ 3 (0.90) and F = 4 (0.92) in the estimation group and those for F ≥ 3 (0.93) and F = 4 (0.97) in the validation group were the highest among the 5 methods examined. The accuracy of the Fibro-Stiffness index had highest values for F ≥ 2, F ≥ 3 and F = 4 in both the estimation and validation groups. The diagnostic performance for F = 4 was improved by a combination of the Fibro-Stiffness index with serum hyaluronic acid level. CONCLUSION: The Fibro-Stiffness index was constructed and validated. It showed superior diagnostic performance to other indices for F ≥ 2, 3 and 4.